New research published in Science highlights potential of a naturally occurring bacterium to help eradicate malaria
- Details
- Category: GlaxoSmithKline
Research published in Science today shows that a naturally occurring bacterium discovered by GSK scientists - Delftia tsuruhatensis Tres Cantos 1 (TC1) - could be the basis for new anti-malarial interventions. Studies done in collaboration at the Johns Hopkins Malaria Research Institute at Johns Hopkins Bloomberg School of Public Health show that the bacterium can significantly reduce the malaria parasite load in both the mosquito midgut and salivary glands indicating the potential of TC1 to inhibit transmission of the parasite to humans via the mosquito.
AI drives new era of target identification and drug design
- Details
- Category: Business
Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact. A new opinion paper in the Cell Press journal Trends in Pharmacological Sciences traces the history of target discovery methods - from experimental approaches, to
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
- Details
- Category: AstraZeneca
Alexion, AstraZeneca Rare Disease, announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). The agreement furthers Alexion and AstraZeneca's commitment to advancing next-generation genomic medicines with the addition of complementary pipeline assets and innovative technologies.
Pfizer announces executive leadership to advance oncology research and development strategy
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.
Effective today, Chris Boshoff, M.D., PhD, will join Pfizer's Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to
AbbVie and Calibr expand strategic collaboration to advance several preclinical and early-stage clinical assets
- Details
- Category: AbbVie
AbbVie (NYSE: ABBV) and Calibr today announced an expanded strategic collaboration to advance several innovative preclinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest. This partnership is an expansion of the collaboration AbbVie and Scripps Research formed in 2019 to develop a broad range of potential new and novel therapeutics.
Pfizer announces New England Journal of Medicine publication on Group B Streptococcus (GBS) maternal vaccine candidate
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being developed for maternal administration to protect infants against invasive GBS disease. In stage two of the three-part study, which enrolled 360 healthy pregnant individuals, GBS6 generated robust maternal antibody responses against the six GBS CPS serotypes included in the vaccine, and these antibodies were efficiently transferred to infants at ratios of ~0.4-1.3 depending on GBS6 group.
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
- Details
- Category: Novartis
Novartis has acquired DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
DTx’s lead program, DTx-1252 targets the root cause of CMT1A - the overexpression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally.
More Pharma News ...
- Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs
- AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
- AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine
- Bayer extends partnership with Peking University to foster pharmaceutical innovation in China
- FDA approves Pfizer's NGENLA™, a long-acting once-weekly treatment for pediatric growth hormone deficiency
- Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations
- FDA accepts Pfizer's application for hemophilia B gene therapy fidanacogene elaparvovec